FDA recall record

Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only recall — FDA D-1545-2022

Lack of Assurance of Sterility

Class IIclassification
D-1545-2022official record ID
Oct 5, 2022report date

Recall record at a glance

Official recordD-1545-2022
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmCIPLA
Report dateOct 5, 2022
Recall initiation dateSep 15, 2022
Quantity641,160 ampules
LocationWarren, NJ, United States

Official product description

Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Suspension, Manufactured by: Cipla Ltd., India, Manufactured for Cipla USA Inc., Warren NJ, NDC# 69097-318-86.

Why the product was recalled

Lack of Assurance of Sterility

Distribution information

Nationwide in the USA and Puerto Rico

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.